Clinical Trial

Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if BiTE-EV works to treat relapsed/refractory acute B-cell leukemia in adults. It will also learn about the safety of BiTE-EV. The main questions it aims to answer are: Can BiTE-EV effectively treat relapsed/refractory acute B-cell lymphoblastic leukemia? What medical problems do participants have when taking BiTE-EV? Participants will: Take BiTE-EV every other day for 1 or 2 months Keep a diary of their symptoms during the medication period During the follow-up period, visit the clinic once every 4 weeks for checkups and tests
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-17.
Trial Details
NCT Number NCT06890494
Lead Sponsor Beijing GoBroad Hospital
Conditions Leukemia
Enrollment 3 participants
Start Date 2025-01-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10